For weight reduction in adults, the Wegovy injection label names two maintenance amounts, 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and instructs prescribers to weigh treatment response and tolerability when choosing between them. A lower settling point is therefore a labeled option that a clinician selects, not something a patient arranges alone.
By Dr. David Nazarian, MD, Internal Medicine
What the escalation schedule actually specifies
Titration for Wegovy injection covers sixteen weeks before any maintenance amount is reached. Each step lasts four weeks, and the stated purpose of the ramp is reducing the risk of gastrointestinal reactions rather than delivering partial benefit along the way.
| Weeks | Once-weekly injected amount | Status in the labeling |
|---|---|---|
| 1 to 4 | 0.25 mg | Starting amount |
| 5 to 8 | 0.5 mg | Escalation step |
| 9 to 12 | 1 mg | Escalation step |
| 13 to 16 | 1.7 mg | Escalation step, and also a named maintenance option |
| 17 onward | Maintenance amount by indication | 1.7 mg or 2.4 mg for weight reduction in adults, 2.4 mg recommended |
The row that changes the conversation is week 13 to 16. The 1.7 mg step is not only a waypoint. It reappears as one of two maintenance amounts the label lists for adults being treated for weight reduction, and for cardiovascular risk reduction as well.
Recommended is not the same as required
Labeling language is precise in a way that plain reading often flattens. Naming 2.4 mg as recommended while listing 1.7 mg alongside it signals a default rather than a mandate. The instruction attached to that choice asks the prescriber to consider both response and tolerability, which is an explicit invitation to individualize.
There is a further step above the default. Adults who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated may go to a maximum of 7.2 mg once weekly. That higher amount was studied in the STEP UP phase 3b trial, and its existence makes the point that this is a range of options rather than a single finishing line.
Seeing the labeled ramp laid out before a visit tends to shorten the conversation about it. Several providers restate the step amounts and the two maintenance figures in patient-facing terms, with Ro, Henry Meds, and Hims and Hers each doing it a little differently and a page such as HealthRX’s Wegovy overview covering the same 1.7 mg and 2.4 mg endpoints. Reading two or three side by side makes the difference between a waypoint and a destination obvious.
What happens when a step is not tolerated
The labeling addresses this directly. If a patient does not tolerate a dose during escalation, it directs that delaying escalation for four weeks be considered. Nothing in that text treats a delay as failure or as a deviation requiring justification.
The pattern of symptoms explains why the provision exists. Nausea, vomiting, diarrhea, and constipation sit among the most frequently reported reactions, and they cluster around the weeks after an increase before easing at a steady amount. Severe gastrointestinal reactions were reported in 4.1 percent of Wegovy injection recipients against 0.9 percent on placebo in adult weight-reduction trials, which is a real signal and also a minority experience.
The evidence question people skip
Here is where honesty matters more than reassurance. The weight-loss numbers circulating publicly come from trials in which participants reached the higher maintenance amount. STEP 1 randomized adults with overweight or obesity to 2.4 mg once weekly, and its results describe that group. A person who settles at 1.7 mg is not covered by that headline figure.
Earlier dose-ranging work points the same way. A phase 2 trial comparing semaglutide against liraglutide and placebo found weight loss increasing across the amounts tested, alongside gastrointestinal reactions that also rose with the amount. Effect and side effects move together because they share a mechanism, which is precisely why the trade is a judgment rather than an obvious call.
So the accurate framing is not that a lower amount works just as well. It is that a lower amount may deliver a smaller effect, that the size of the gap in any individual case is not predictable from trial averages, and that a treatment someone stays on generally beats one they abandon. Real-world cohort work on GLP-1 receptor agonists has repeatedly found that many people never reach or never stay at the higher amounts.
Cost belongs in the conversation, stated plainly
Pretending money is not a factor helps nobody. Coverage for weight-management medication varies by plan and by employer, and Medicare Part D handles obesity drugs differently from drugs for other conditions, so a substantial number of people are paying cash. That pressure is real, and it reaches the exam room whether or not anyone names it.
What it should not become is a private decision to ration medication. The productive version is telling the prescriber the actual constraint so the plan can be built around it, including whether a lower maintenance amount is defensible for that person and what the likely trade looks like. Access routes differ here too. Endocrinology practices, manufacturer channels such as NovoCare Pharmacy, and telehealth services including Ro, Hims & Hers, LifeMD, and formblends.com publish different pricing structures and handle follow-up questions on different timelines, which is worth comparing before a difficult month rather than during one.
The tablet form escalates on its own scale
Wegovy tablets are dosed daily rather than weekly and follow a separate schedule: 1.5 mg for the first thirty days, 4 mg for the next thirty, 9 mg for the next thirty, and 25 mg as maintenance from day 91. If the 25 mg maintenance amount is not tolerated, the labeling suggests considering a switch to Wegovy injection at 1.7 mg once weekly.
That instruction is a useful illustration of how the label treats intolerance. The answer it reaches for is a different formulation or a different maintenance amount, arranged deliberately, rather than an unstructured reduction.
Compounded semaglutide sits outside all of this
Compounded drugs are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality. Concentration in a compounded vial is set by the pharmacy, so none of the amounts above describe what such a vial contains and no published escalation schedule exists for one. Any titration plan for a compounded preparation comes from the prescriber who wrote it.
One prerequisite applies across every version of this drug. Semaglutide carries a boxed warning for thyroid C-cell tumors observed in rodent studies, and use is ruled out in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Concurrent use with another GLP-1 receptor agonist is also not recommended.
Frequently asked questions
Is 1.7 mg an off-label amount for weight management?
No. The labeling lists 1.7 mg alongside 2.4 mg as maintenance amounts for weight reduction in adults, with 2.4 mg recommended. Choosing between them is a prescriber decision informed by response and tolerability, so the question to raise is whether it fits a particular case.
How long can escalation be delayed?
The labeling directs considering a four-week delay when a step is not tolerated, without framing repeated delays as prohibited. How many times that is reasonable, and whether a different maintenance target makes more sense, is a clinical judgment rather than a fixed number written into the schedule.
Does staying lower avoid side effects entirely?
It reduces the likelihood of the reactions that scale with amount, particularly gastrointestinal ones. It does not remove the label’s warnings, which cover pancreatitis, gallbladder disease, kidney injury from dehydration, and heart rate increases without setting a threshold below which they stop applying.
What if the higher amount was tolerated but is unaffordable?
That is a legitimate thing to raise directly rather than solve quietly. The prescriber can weigh what a lower maintenance amount is likely to cost in effect, and can also check coverage routes, manufacturer channels, and formulation alternatives that might not have been considered at the outset.
